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Strategies to overcome resistance to anti-EGFR monoclonal 
antibodies in colorectal cancer 
 
ABSTRACT 
In the past few years, knowledge on the resistance 
to therapy with monoclonal antibodies in colorectal 
cancer has evidenced the role of mutations in a series 
of proteins involved in the epidermal growth factor 
receptor (EGFR) pathway. KRAS mutations can 
influence the response to therapy, as demonstrated 
by clinical utilization of cetuximab and panitumumab 
that are indicated only in KRAS wild-type colorectal 
cancer. Recently, it has been demonstrated that the 
mutational status of other proteins like NRAS, BRAF, 
PI3K or alterations in EGFR and other tyrosine kinase 
receptors are involved both in primary and secondary 
resistance to anti-EGFR monoclonal antibodies and 
could predict the patient response and survival. Many 
therapeutic strategies have been studied to overcome 
resistance to these drugs, which include the use of 
drugs directed against proteins involved in the 
intracellular signalling pathway of EGFR, such as 
inhibitors of MEK, BRAF, PI3K/mTOR, or directed 
against other tyrosine kinase receptors such as MET 
and HER2. This review will analyse recent strategies 
utilized to overcome resistance to anti-EGFR 
monoclonal antibodies in colorectal cancer.  
KEYWORDS: colorectal cancer, cetuximab, mAbs 
resistance, panitumumab  
 
ABBREVIATIONS 
CRC  : colorectal cancer 
EGFR  : epidermal growth factor receptor 
EMA   : European Medicines Agency 
ERK  : extracellular signal-regulated kinases 
FOLFIRI  : folinic acid, fluorouracil, irinotecan 
FOLFOX  : folinic acid, fluorouracil, oxaliplatin 
HER2  : human epidermal growth factor  
   receptor 2 
KRAS  : V-KI-RAS2 kirsten rat sarcoma viral 
   oncogene homolog 
mAb  : monoclonal antibody 
MAPK  : mitogen-activated protein kinase 
mCRC  : metastatic colorectal cancer 
OS  : overall survival 
PFS : progression-free survival 
PI3K  : phosphatidylinositol-4,5-bisphosphate 
   3-kinase 
PR  : partial response  
PD  : progression disease  
PTEN  : phosphatase and tensin homolog 
RAF  : rapidly accelerated fibrosarcoma 
RR  : response rate 
SD : stable disease 
VEGFR2 : vascular endothelial growth factor 2 
 
INTRODUCTION 
Colorectal cancer (CRC) is a major cause of 
morbidity and mortality throughout the world: it is 
estimated that there are more than 1.4 million men 
and women in the United States with a previous 
CRC diagnosis, and an additional 134.490 cases 
were diagnosed in 2016 [1, 2]. CRC is the third 
cause of cancer deaths among men and women in 
the United States [2] and the second in European 
Union [3]. The prognosis of patients with metastatic 
CRC (mCRC) has improved in the last15 years, 
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thanks to the introduction of chemotherapy drugs 
such as fluropyrimidines, oxaliplatin, and irinotecan, 
and molecular targeted drugs such as regorafenib, 
aflibercept and monoclonal antibodies (mAbs) 
like cetuximab, panitumumab and bevacizumab 
[4, 5].  
Cetuximab and panitumumab are mAbs directed 
towards epidermal growth factor receptor (EGFR); 
they bind to the extracellular domain of this receptor, 
thus inhibiting its activation and its downstream 
intracellular signals, in particular the RAS–RAF–
MEK–MAPK and the PTEN–PIK3CA–AKT 
pathways [6]. Undoubtedly they represent the 
greatest step towards the treatment of CRC in terms 
of progression-free survival (PFS), overall survival 
(OS), response rate (RR), and quality of life among 
different lines of treatment [7]. Unfortunately, anti-
EGFR antibodies are effective only in a restricted 
subset of patients because of the development of 
several mechanisms of resistance and the lack of 
clinical and molecular biomarkers that could 
predict treatment response. When cetuximab and 
panitumumab were used as single agents in unselected 
patients with chemotherapy-refractory mCRC, they 
achieved a RR of only 10% [8, 9]; CRC often 
harbour genetic alterations in proteins of the EGFR 
pathway responsible for the treatment failure 
(intrinsic or primary resistance). Moreover, even 
in patients who initially respond to anti-EGFR 
monoclonal antibodies, the duration of this response 
is restricted and does not last more than 3-18 months, 
because of the appearance of genetic alterations 
responsible for acquired or secondary resistance [10].  
Genomic alterations in the downstream effectors 
of the EGFR pathway are the most common 
mechanisms of resistance; first of all, randomized 
phase III trials demonstrated that chemorefractory 
mCRCs carrying KRAS mutations were resistant 
to the treatment with anti-EGFR mAbs, and therefore 
both Food and Drug Administration and European 
Medicines Agency (EMA) restricted the use of 
cetuximab and panitumumab to patients with 
KRAS wild-type mCRC [4, 11, 12]. 
Recently, other alterations in EGFR signalling 
pathway are recognized as involved in anti-EGFR 
drug resistance, such as mutations in NRAS 
and BRAF [13], alteration in PI3K/AKT/mTOR 
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pathway [13-15], amplification of HER2 [16], and 
mutations in tyrosine kinase receptors such as EGFR 
[17, 18], HER3 [19] and MET [20].  
These genetic alterations are biochemically 
responsible for the activation of MEK/ERK pathway 
and have been recognised in both primary and 
secondary resistance, except for rare mutations in 
the extracellular domain or in tyrosine kinase 
domain of EGFR, which have been only identified 
for acquired resistance [10].  
 
RAS/RAF 
RAS mutations have a key role in the mechanisms 
of both primary and acquired resistance to anti-
EGFR mAbs. RAS mutations compromise the 
intrinsic ATPase activity of RAS, causing an 
accumulation of mutant proteins in the active 
conformation, thus leading to constitutive activation 
of MAPK pathway even in the presence of EGFR 
inhibitors [7, 21]. The RAS genes have been 
reported to be mutated in approximately 40%-50% 
of CRCs [22]; the most common RAS mutation is 
in KRAS exon 2 (42.6%), followed by KRAS 
exon 3 (3.8%) and KRAS exon 4 (6.2%), NRAS 
exon 2 (2.9%), NRAS exon 3 (4.2%) and NRAS 
exon 4 (0.3%) [21, 23]. The most frequent KRAS 
exon 2 mutations are in codons G12D, G12V and 
G12C, KRAS exon 3 are in codons Q61H and Q61R, 
KRAS exon 4 are in codons A146T and A146V, 
NRAS exon 2 in codon G12D, NRAS exon 3 in 
codons Q61K and Q61R and NRAS exon 4 in codon 
A146T [21].  
Preclinical data and retrospective analysis from 
phase III clinical studies suggested that not all 
KRAS mutations have the same negative predictive 
role and that patients with KRAS G13D mutation 
can achieve a benefit from cetuximab in both first-
line and advance-line treatments [24, 25]. This 
observation was not confirmed by meta-analysis 
and prospective trial, in which no statistical 
difference in terms of PFS or OS was observed 
between patients carrying KRAS G13D and other 
KRAS mutations with cetuximab monotherapy or 
cetuximab plus irinotecan [26, 27].  
The mutational status of KRAS is concordant 
between primary tumours and metastasis, suggesting 
that these mutations have an essential role in the 
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with a lack of prospective studies, do not allow 
establishing the predictive role of BRAF mutation 
for treatment with cetuximab and panitumumab. 
BRAF mutation has been also recognized as a 
mechanism of acquired resistance to anti-EGFR 
therapy [44].  
 
PI3K/PTEN 
Alterations in genes that encode for PIK3CA/
AKT/mTOR signalling pathway are involved in 
the development of malignant tumours and could 
impair the response to anti-EGFR mAbs. Mutations 
of PIK3CA and loss of PTEN, which result in the 
pathological activation of this pathway, were observed 
in patients with CRC resistant to anti-EGFR 
antibodies: they occur in 10-20% and 30% of CRCs, 
respectively [45]. Even though in preclinical models 
the alterations in this pathway were found to be 
predictive of the therapy failure with these drugs 
[46, 47], they were not clinically validated as 
predictive markers because PI3KCA and PTEN 
alterations are often concomitant with RAS and/or 
BRAF mutations, and PTEN expression has been 
associated with outcome only in metastases but 
not in primary tumours [48]. Moreover, only 
PIK3CA exon 20 mutations were predictive of a 
lack of response to cetuximab in the KRAS wild-
type subpopulation, whereas PIK3CA exon 9 mutation 
was associated with KRAS mutations, suggesting 
a secondary role of PIK3CA exon 9 mutations in 
cetuximab efficacy [49, 50]. 
 
Alteration in tyrosine kinase receptors 
Both HER2 amplification and HER3 mutations 
were associated with poor response to anti-EGFR 
antibodies. HER2 amplification has been described 
in a small percentage of CRC patients (2-3%), but 
the frequency was higher in KRAS wild-type 
patients resistant to cetuximab (13.6%) and in up 
to 36% of xenopatients in the subset of quadruple 
wild-type (KRAS, NRAS, BRAF and PIK3CA) in 
which cetuximab was ineffective [16]. HER3 
mutations have been found in approximately 11% 
of colon and gastric cancers and they can limit the 
responsiveness to EGFR inhibitors, even if HER2 
is not amplified [19]. 
Secondary resistance could also be associated with 
EGFR mutations, which may occur in approximately 
 
early phase of tumorigenesis and that they are 
conserved during tumour progression [7]. 
These mutations also drive secondary resistance 
to anti-EGFR therapy in 50-80% of patients; they 
may be present in a small fraction of cells within
the tumour before treatment initiation and then 
may be selected by pressure from the anti-EGFR 
treatments or arise as a result of continued 
mutagenesis during the treatment [28, 29]. In both 
primary and secondary resistance, a small percentage 
of patients (0.7%) present KRAS amplification 
[30] that seems to be mutually exclusive with 
other KRAS or BRAF mutations.  
10-20% of patients with CRC carried a mutation 
on BRAF, a serine/threonine protein kinase which 
is the first downstream effector of RAS [31, 32]; 
BRAF mutations have been also reported in 
melanoma, thyroid and ovarian cancer with a 
frequency of up to 70%, 45%, and 30%, respectively 
[31, 33, 34]. 
The most common BRAF mutation is the V600E 
point mutation in the kinase domain, derived from 
a thymidine-to-adenine substitution at nucleotide 
1799, which results in the replacement of valine 
600 mostly with glutamic acid. This point mutation 
alters the conformation of the catalytic domain 
activating the protein kinase activity and the 
downstream ERK/MAPK pathway [21, 31, 35]. This 
mutation accounts for 80% of all BRAF mutations 
[31]. Several clinical studies have demonstrated 
that the presence of BRAF mutations predicts 
resistance to anti-EGFR therapies and is a marker 
of poor prognosis. Even though BRAF V600E is 
generally mutually exclusive with RAS mutations, 
recent studies have demonstrated the coexistence 
of BRAF mutations with others, including TP53, 
KRAS and PIK3CA exon 9 and exon 20 [7, 36, 37]. 
While the association of the BRAF V600E mutations 
and colon cancer mortality is well established [38, 39], 
its role as a predictive biomarker to anti-EGFR 
treatments is not clearly understood: several studies 
have showed that patients carrying a BRAF mutation 
do not achieve any benefit from anti-EGFR treatments 
in second-line or in later lines of therapy [38, 40]. 
However, data from the first-line setting are often 
contradictory [20, 41-43]. Probably, the small 
percentage of BRAF mutated patients, together 
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to anti-EGFR mAbs in CRC. Yoon et al. [54] provided 
in vivo evidence of therapeutic strategy to overcome 
cetuximab resistance due to KRAS mutation using 
a xenograft tumour model of CRC treated with 
selumetinib. Other studies evidenced the possibility 
to combine selumetinib and cetuximab to obtain 
an inhibition of proliferation in cell lines resistant 
to cetuximab harbouring KRAS mutations [10]. A 
phase I study was undertaken to determine the 
tolerability and pharmacokinetic profiles of the 
combination of selumetinib and cetuximab, with an 
expanded cohort in KRAS-mutant CRC. Selumetinib 
was administered orally at 50 mg daily or 50-75 mg 
twice daily and cetuximab was administered at 
standard doses; cycles were repeated every 28 days. 
In the expanded cohort, five patients showed stable 
disease (SD), while nine patients had progression 
disease (PD) among fourteen evaluable patients 
[55]. Another highly selective, orally bioavailable, 
small-molecule inhibitor of the MEK1/2 kinases 
is pimasertib. Several studies have demonstrated 
that pimasertib possessed potent antitumor activity 
either alone or in combination with other agents in 
cell lines and xenograft models [54, 56]. In a 
phase I study, patients with KRAS mutant mCRC 
were treated in the second-line setting with 
FOLFIRI plus pimasertib [57]. Sixteen patients 
were enrolled, and of the fifteen patients in the 
efficacy analysis set, nine experienced SD, two 
had a partial response (PR) and three had PD as 
their best overall response. SD was maintained for 
at least 12 weeks in six of nine patients [57].  
Thereafter, the importance of BRAF in the onset 
of resistance in patients treated with anti-EGFR 
mAbs was evidenced. Also for BRAF, the clinical 
approach to treat patients harbouring BRAF mutations 
was initially based on the use of selective BRAF 
inhibitors such as vemurafenib and dabrafenib. 
Vemurafenib and dabrafenib are oral BRAF 
inhibitors, able to inhibit BRAF kinases with 
activating codon 600 mutations. Vemurafenib is 
indicated in monotherapy for the treatment of adult 
patients with unresectable or metastatic melanoma 
with a BRAF V600 mutation [58]; dabrafenib shows 
the same indications, but can be administered as 
monotherapy or in combination with trametinib 
[59]. In a phase II study, vemurafenib was 
administered at 960 mg twice daily in monotherapy 
 
 
20% of patients treated with cetuximab and 1% of 
patients treated with panitumumab [51]. The most 
frequent mutations recognized in patients, namely 
S492R, R451C and K467T, involved the extracellular 
domain of the receptor and, except for R451C, are 
located in the cetuximab-binding region, thus 
preventing the binding of cetuximab to the receptor, 
but not of panitumumab [17, 18]. CRC cell lines 
made resistant to cetuximab can present other EGFR 
variants such as S464L, G465R and I491M [17], 
whereas mutations in the EGFR kinase domain at 
codons 714 and 794 were identified in circulating 
DNA of patients with secondary resistance [44].  
MET, a tyrosine kinase receptor activated by 
hepatocyte growth factor and involved in several 
cell processes, could be amplified in approximately 
2% of mCRCs [52]. MET amplification is responsible 
for the development of distant metastases and it is 
associated with poor outcomes; moreover, MET 
amplification has been recognized as a mechanism 
of both primary and acquired resistance to anti-
EGFR therapies in patients with KRAS wild-type 
mCRC. In cetuximab-resistant xenopatients which 
are wild-type for RAS, BRAF, PIK3CA and 
HER2 the rate of MET amplification is increased 
(12.5%) [20]. 
 
Strategies to overcome resistance to  
anti-EGFR mAbs 
As earlier data showed that resistance was mainly 
linked to the presence of mutations in the EGFR 
and its pathway, many studies, both at preclinical 
and clinical levels, were performed utilising inhibitors 
of proteins situated in this signalling pathway. 
One of the first approaches utilized to overcome 
resistance to anti-EGFR mAbs was based on the 
use of MEK1/2 inhibitors, as direct inhibition of 
KRAS showed an absence of clinical efficacy [7]. 
Several MEK1/2 inhibitors have been studied but 
the first generation of these compounds did not 
progress to clinical trials due to their severe toxicity 
or undesirable pharmaceutical properties [53].  
Selumetinib, a highly selective and potent 
uncompetitive oral inhibitor of MEK1/2, was able 
to prevent ERK1/2-mediated growth factor-
independent survival. Preclinical data showed that 
selumetinib could be effective to overcome resistance 
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Anyway, a phase II study in which sorafenib was 
administered at 400 mg orally twice daily with 
intravenous cetuximab weekly in 28-day cycles in 
KRAS-mutated (codons 12 or 13), evidenced the 
absence of objective responses in the twenty-six 
patients treated [69]. 
As BRAF V600E mutation leads to the activation 
of the MEK/ERK pathway, inhibitors of these 
kinases were tested, at a later time, in mCRCs 
harbouring BRAF and KRAS mutations.  
Trametinib, an oral, reversible, highly selective, 
allosteric inhibitor of MEK1/2 activation and kinase 
activity, is indicated as monotherapy or in combination 
with dabrafenib for the treatment of adult patients 
with unresectable or metastatic melanoma with a 
BRAF V600 mutation [70]. Infante et al. [71] treated 
twenty-eight patients with advanced CRC, treatment-
refractory KRAS- or BRAF-mutant, with trametinib. 
In this phase I study, the drug was administered at 
2 mg daily for 21 days (every 28 days) but no patients 
achieved an objective response. Presently, several 
clinical trials are underway, where trametinib is 
used in combination with other drugs. An open-
label phase I/II multi-centre study was designed 
with the aim to identify the effect of lapatinib plus 
trametinib in patients with KRAS mutation and 
PIK3CA wild-type mCRC and other types of solid 
tumours [72].  
Also for another molecular target, PI3K, identified 
as crucial for the onset of resistance, the selective 
inhibition or the inhibition of its downstream 
effectors, such as mTOR or AKT, did not achieve 
significant clinical results. In an isogenic cellular 
model, tumour cells carrying oncogenic PIK3CA 
mutations or PTEN loss of function were sensitive 
to everolimus, an mTOR inhibitor, except when 
KRAS or BRAF mutations were concomitantly 
present [73]. Translating these findings into the 
clinical setting by performing genetic analysis of 
tumours from patients treated with everolimus, it 
was evidenced that cancer patients whose tumours 
carried PIK3CA mutations in the kinase domain 
or PTEN loss of function, displayed increased clinical 
benefit from everolimus treatment, except in the 
presence of KRAS mutations [73]. A phase I 
study in patients with advanced solid tumours was 
carried out in order to identify everolimus doses 
for cancer treatment. Fifty-five patients were recruited 
 
in twenty-one patients with chemorefractory mCRC 
harbouring BRAF mutations. Among these patients, 
no one achieved complete response (CR), one patient 
had a confirmed PR, and seven other patients had 
SD as the best response for at least 8 weeks [60]. 
Also with dabrafenib the response in CRC was 
not excellent: in 9 of colorectal patients included 
in a phase I study, aimed to evaluate safety and 
tolerability of this drug in patients with incurable 
solid tumours, only one had a confirmed PR, while 
seven showed a SD [61]. As many observations 
indicated that the inhibition of BRAF was able to 
activate EGFR signalling pathway [62], another 
approach was to associate EGFR and BRAF inhibitors. 
Currently, several phase I/II clinical trials are under 
investigation in which vemurafenib is associated 
with cetuximab and irinotecan [63], cetuximab and 
fluoropyrimidines [64] or panitumumab [65]. The 
results of one of these studies were very recently 
published, which showed that six of seventeen 
evaluable patients (35%) achieved a radiographic 
response by RECIST criteria; these data were 
consistent with in vivo models, demonstrating tumour 
regression with the triplet regimen based on 
cetuximab, irinotecan and vemurafenib [66]. 
Dabrafenib, instead, is under investigation in a 
phase I/II clinical trial in combination with trametinib, 
panitumumab and 5-fluorouracil, in subjects with 
BRAF-mutation V600E positive CRC and in subjects 
with CRC with secondary resistance to prior anti-
EGFR therapy [67]. Currently, despite the excellent 
results obtained with vemurafenib and dabrafenib 
in melanoma with BRAF V600E mutation, we can 
conclude that in CRC these drugs do not show 
significant clinical activity in patients with the 
same mutation. 
Di Nicolantonio et al. [38] studied the role of BRAF 
in CRC response to anti-EGFR mAb therapy. In 
this paper, in vitro data showed that colorectal cell 
lines treated with a combination of cetuximab and 
sorafenib were dramatically sensitive to the treatment, 
whereas single agents, alone, had limited effects 
[38]. Hence, the authors hypothesized that the 
simultaneous inhibition of EGFR and KRAS/ 
BRAF pathway could be a good pharmacological 
approach. Sorafenib is a multikinase inhibitor, which 
has demonstrated both anti-proliferative and anti-
angiogenic properties in vitro and in vivo [68]. 
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signals and impaired cancer cell migration. These 
data suggest that EGFR and MET inhibition could 
represent a strategy to overcome cetuximab resistance 
in CRC patients. Moreover, in a mouse CRC 
xenograft model, cabozantinib, a c-MET and 
VEGFR2 inhibitor, was used to evaluate its effect 
on in vivo growth of tumours and angiogenesis [81], 
underlining again that MET inhibition could be a 
potential strategy in the treatment of resistant CRC. 
The results obtained with almost all of the kinase 
inhibitors surely are interesting but, till now, without 
a significant clinical impact. More interesting results 
were obtained with regorafenib. Regorafenib is a low 
molecular weight, orally available, inhibitor of 
multiple protein kinases, including kinases involved 
in tumour angiogenesis (VEGFR1, -2, -3, TIE2), 
oncogenesis (KIT, RET, RAF-1, BRAF, 
BRAFV600E), and the tumour microenvironment 
(PDGFR, FGFR) [82]. In preclinical studies, 
regorafenib has demonstrated antitumor activity in 
a broad spectrum of tumour models including 
colorectal tumour models, which is mediated both 
by its antiangiogenic and antiproliferative effects. 
Regorafenib is indicated for the treatment of adult 
patients with mCRC who have been previously 
treated with, or are not considered candidates for, 
available therapies. These include fluoropyrimidine-
based chemotherapy, an anti-VEGF therapy and an 
anti-EGFR therapy [82]. The first-in-man phase I 
clinical trials of regorafenib assessed the preliminary 
evidence of antitumor activity of this drugs in CRC 
[83]. Hence the trial was expanded and focused on 
CRC. 38 patients previously heavily treated for CRC 
were recruited, and received oral regorafenib at 
60–220 mg daily (160 mg daily in the extension 
cohort) for 21 days and 7 days of no treatment. 
Among the twenty-seven patients evaluable for 
response, one achieved PR and nineteen had SD 
[84]. In a phase Ib trial, fourty-five patients were 
treated with regorafenib (160 mg daily) in 
combination with FOLFOX or FOLFIRI as first- 
or second-line treatment of colorectal cancer. 
Among the thirty-eight patients evaluable for tumour 
response, seven achieved a PR, while twenty-six 
showed SD as the best response [85]. Finally, an 
international, multicentre, randomised, placebo-
controlled, phase III trial dissected the efficacy 
of regorafenib in monotherapy for previously 
treated mCRC (CORRECT) [86]. 760 patients were
 
and clinical benefit was observed in four patients, 
including one patient with advanced colorectal 
cancer that achieved a PR [74]. In a phase II clinical 
trial, everolimus at 70 mg weekly or 10 mg daily 
was well tolerated but did not confer meaningful 
efficacy in heavily pre-treated patients with mCRC 
[75]. Currently, several trials evaluating combinations 
of PI3K/mTOR with MEK inhibitors are ongoing. 
A phase I study tested a combination of two 
experimental drugs, pimasertib and SAR245409, a 
PI3K/mTOR inhibitor, in the treatment of locally 
advanced or metastatic solid tumours. Fifty-three 
patients were enrolled and among the sixteen CRC 
recruited, four PRs were evidenced (1 patient was 
KRAS mutated) [76, 77]. Another open-label, 
dose-finding, phase Ib clinical trial was designed to 
evaluate the effects of the orally administered PI3K/ 
mTOR inhibitor BEZ235 in combination with the 
MEK1/2 inhibitor MEK162 [78]. 
Another possible strategy to overcome cetuximab 
resistance in CRC could be the administration of 
anti-EGFR/HER2 drugs such as the small molecule 
inhibitor lapatinib or the monoclonal antibody 
pertuzumab. Bertotti et al. [16], published a study 
in which xenopatients with cetuximab-resistant, 
quadruple-negative, HER-2-amplified mCRC were 
treated with lapatinib and cetuximab or pertuzumab. 
Based on the positive results obtained in this study, 
the HERACLES trial was designed. This was a 
multicentre open-label phase II trial in which patients 
with KRAS exon 2 (codons 12 and 13) wild-type 
and HER2-amplified mCRC resistant to standard 
therapies, including anti-EGFR mAbs, were recruited 
to evaluate the RR of trastuzumab in association 
with lapatinib or pertuzumab. Recently, the results 
of the association of trastuzumab and lapatinib were 
published; eight of the twenty-seven enrolled patients 
achieved an objective response, one patient achieved 
a CR and seven PRs; twelve patients had SD. 
Moreover, the combination was well tolerated, as 
no grade 4 or 5 adverse events were reported [79]. 
Troiani et al. [80], unravelled the role of MET in 
mediating cetuximab resistance in colorectal cancer 
cells, suggesting that the interaction of EGFR and 
MET was responsible for the overexpression of 
TGF-α, a specific EGFR ligand. They utilized a 
selective MET inhibitor, PHA665752, showing its 
ability to inhibit cell growth, proliferation, survival 
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randomized to receive regorafenib (505 patients; 
160 mg regorafenib daily) or placebo (n = 255) for 
the first 3 weeks of each 4-week cycle until disease 
progression, death, or unacceptable toxic effects. PR 
or SD was achieved in 207 (41%) of the 505 patients 
assigned to regorafenib and 38 (15%) patients 
assigned to placebo. Five patients assigned to 
regorafenib and one patient assigned to placebo 
had a PR and no patients had a CR. This study showed 
for the first time an overall survival benefit of a small 
molecule kinase inhibitor in patients with mCRC 
refractory to treatment [86]. 
Currently, several phase I/III trials are ongoing with 
the aim to dissect the role of regorafenib in patients 
with mCRC who have progressed after standard 
therapy [87] or in combination with others 
chemiotherapy regimens such as FOLFIRI [88], 
cetuximab [89-90] or panitumumab [91]. 
 
CONCLUSION 
Although the molecular and clinical advancement 
over the past few years have allowed to increase the 
PFS and OS in patients with mCRC, the onset of 
resistance to anti-EGFR mAb therapy remains one 
of the main clinical problems. In general, selective 
inhibition of a single kinase is not a successful 
strategy to treat resistant patients, maybe because 
these very selective drugs are effective only in a 
small subset of patients. In fact, regorafenib, an 
inhibitor of multiple protein kinases, was the only 
drug able to induce a response in a high percentage 
of patients when administered in monotherapy [86]. 
The combination of two or more drugs in complex 
chemotherapy schemes seems to be a promising 
approach after the first line of treatment. One of the 
most exciting strategies that is emerging is 
undoubtedly the possibility to target HER2, with 
both kinase inhibitors and mAbs [79]. In conclusion, 
the enhancement of genetic and biological knowledge 
to select the right therapy for each patient continues 
to be our aim. 
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